It Took 7 Miscarriages, 10 IVF cycles, 9 Years, and Nearly $200,000 to Solve My Fertility Issues
By Elizabeth Katkin,
Marie Claire
| 06. 15. 2018
After six miscarriages, six fresh in vitro fertilization (IVF) cycles, two frozen IVF cycles, and one healthy not yet two-year-old daughter, I was told by my New York–based fertility specialist and embryologist to give up on having another genetic child. I had just turned 40. Though I had spent nearly $200,000 on fertility treatments in the U.S. and the U.K.—a staggering sum—my previous two IVF cycles had produced precisely zero useable embryos. The seasoned professionals at my clinic in New York gently told me that it was time to face facts: I likely had no good eggs left. Experts I had seen over the previous eight years echoed their opinion.
Throughout the course of my fertility journey, I had been “blessed” with the ability to produce lots of eggs. The IVF cycle that brought us our daughter had been no different than its predecessors: twenty-eight eggs retrieved, seventeen fertilized, and thirteen mature embryos on the third day of their existence—science-speak for a reassuringly ample supply. But genetic testing revealed a startling result: only three of our embryos were chromosomally normal...
Related Articles
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...